Physician profile
David M Leon
NPI 1174605737
$3,835.89
in general payments reported to CMS, 2019-2025
32 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $439 · 2021: $656 · 2022: $363 · 2023: $445 · 2024: $1,204 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064 · Travel and Lodging: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.93 |
| Travel and Lodging | $789.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Transmedics, INC. | $789.44 | 2024 | Organ Care System |
| Pfizer INC. | $387.71 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.03 | 2019-2025 | Jardiance |
| Abbvie INC. | $287.82 | 2021-2025 | |
| Glaxosmithkline, LLC. | $241.39 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $217.99 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $180.40 | 2022-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $141.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $134.31 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $131.35 | 2019-2021 | |
| Astellas Pharma US INC | $125.32 | 2019-2021 | |
| Abbott Laboratories | $86.80 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.38 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $71.28 | 2019-2023 | Seglentis, Livalo |
| Amneal Pharmaceuticals LLC | $68.28 | 2023-2024 | Unithroid, Rytary |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $63.44 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.87 | 2022 | |
| Esperion Therapeutics, INC. | $53.96 | 2021 | |
| Eisai INC. | $48.76 | 2020 | |
| Allergan, INC. | $45.95 | 2019-2020 | |
| Amarin Pharma, INC. | $44.85 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $38.72 | 2020-2021 | |
| Novo Nordisk INC | $29.95 | 2021-2023 | Saxenda, Wegovy |
| Lundbeck LLC | $28.98 | 2024 | Rexulti |
| Seqirus USA INC | $28.71 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $22.97 | 2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $22.13 | 2022 | |
| Inspire Medical Systems, INC. | $20.99 | 2025 | Inspire |
| Radius Health, INC. | $20.04 | 2023 | Tymlos |
| Daiichi Sankyo INC. | $19.30 | 2020 | |
| Sanofi Pasteur INC. | $13.82 | 2022 | |
| Vertical Pharmaceuticals, LLC | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.